Summary

Inflammatory Bowel Disease Treatment Market Trends & Summary

Inflammatory Bowel Disease Treatment Market is expected to reach US$ 33.99 billion 2033 from US$ 22.91 billion in 2024, with a CAGR of 4.48% from 2025 to 2033. Increased disease prevalence, improvements in biologic medicines, increased awareness, better diagnostics, and rising healthcare spending on specialist treatments are all factors propelling the market for treatments for inflammatory bowel disease.

The report Inflammatory Bowel Disease Treatment Market & Forecast covers by Drug Class (TNF Inhibitors, Anti-Integrin, IL inhibitors, JAK inhibitors, Corticosteroids, Aminosalicylates, Others), Disease Indication (Ulcerative Colitis, Crohn's Disease), Distribution Channel (Hospital, Retail, Online), Company and Company 2025-2033.


Inflammatory Bowel Disease Treatment Industry Overview

Chronic illnesses that cause inflammation in the digestive tract, such as Crohn's disease and ulcerative colitis, are included in the category of inflammatory bowel disease (IBD). Reduction of symptoms, remission, and enhancement of quality of life are the goals of treatment. Commonly used medications include immunosuppressants, corticosteroids, aminosalicylates, and biologics (e.g., TNF inhibitors). Biologic treatments focus on particular immune system pathways that contribute to inflammation. Surgery to remove damaged intestinal segments may be required in extreme circumstances. Better management of IBD is facilitated by early diagnosis and more awareness, while improvements in outcomes are being brought about by advances in tailored therapy and biologic medicines.

The prevalence of Crohn's disease and ulcerative colitis is rising globally as a result of a number of reasons, including changes in people's lifestyles and environmental conditions. For example, an article in the Indian Journal of Gastroenterology from 2023 states that inflammatory bowel disease (IBD), which affects about 0.3% of the world's population, is one of the major worldwide health challenges. Furthermore, a greater diagnosis rate, appropriate reimbursement policies in industrialized nations, and a growing emphasis on early disease diagnosis all contribute to the market's expansion. As a result, more people were receiving treatment for IBD, which raised the need for medications to treat the condition, including TNF inhibitors, IL inhibitors, JAK inhibitors, and others in the market.

Globally, the use of treatments for inflammatory bowel disease is rising as more people become aware of the advantages of medications including biologics, corticosteroids, and others. According to a study by Science Direct, for example, of the 655 patients in South America, 36.4% of those with Crohn's disease and 9.1% of those with ulcerative colitis utilized biological therapy.


Growth Drivers for the Inflammatory Bowel Disease Treatment Market

A robust pipeline molecule portfolio is expected to boost product launches over the forecast period.

Some of the factors driving the growth of the inflammatory bowel disease treatment market include the increasing prevalence of Crohn's disease and ulcerative colitis as well as the growing global awareness of the condition. As a result, a number of significant industry participants are concentrating on research and development and investigating novel treatment options for IBD.

For instance, there are now around 145 active clinical trials for Crohn's disease and ulcerative colitis, according to ClinicalTrials.gov. Most of the compounds are in clinical trials in phases three and four. To develop and market PF-06480605 (now RVT-3101), Roivant Sciences established a new Vant in December 2022. A completely human monoclonal antibody called RVT-3101 targets TL1A and is presently being developed in Phase 2b for ulcerative colitis (UC). Pfizer and The Vant have the only right to work together on a next-generation TL1A-directed antibody that just went into Phase 1.

Phase 3 clinical trials were conducted by Eli Lilly and Company to assess the long-term safety and effectiveness of mirikizumab in children and adolescents with Crohn's disease or moderate-to-severe ulcerative colitis.

Furthermore, the growing need for biologics to treat various ailments has prompted market participants to diversify their product lines and launch their medications internationally. Therefore, it is anticipated that the adoption of inflammatory bowel disease therapies would be supported during the forecast period by the growing regulatory approvals for the drugs introduced by the major companies as well as the growing patient preferences for the prescriptions.


Improved diagnostics

Better diagnostics, which allow for earlier detection and more precise disease monitoring, are a major growth driver for the market for drugs to treat inflammatory bowel disease (IBD). More accurate IBD diagnosis and prompt intervention are made possible by genetic profiling, biomarker-based blood testing, and advanced imaging techniques. Personalized therapy plans made possible by early diagnosis improve patient outcomes. The market for tailored and cutting-edge therapeutics for IBD is driven by the improved disease management brought about by evolving diagnostic tools, which also lower hospitalizations and consequences.


Advancements in biologic therapies

One of the main factors propelling the market for treatments for inflammatory bowel disease (IBD) is the development of biologic medicines. For moderate to severe cases of IBD, biologics like TNF inhibitors (e.g., infliximab, adalimumab) and more recent drugs that target particular immune pathways (e.g., integrin inhibitors, IL-12/23 inhibitors) provide tailored therapeutic choices. Compared to conventional medications, these treatments are more successful in achieving long-term remission and improving patients' quality of life. Biologic therapies are becoming more and more popular in the treatment of IBD due to their improved efficacy and decreased side effects, which is propelling market growth and promoting further study and investment in novel treatments.

In June 2021, AbbVie declared that SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, has been authorized by the US FDA to treat individuals with moderately to highly active Crohn's disease (CD). Furthermore, in October 2023, Teva Pharmaceuticals and Sanofi worked together to co-develop and co-commercialize asset TEV'574, which is presently undergoing Phase 2b clinical studies to treat Crohn's disease and ulcerative colitis, two forms of inflammatory bowel disease.


Challenges in the Inflammatory Bowel Disease Treatment Market

Drugs' exorbitant costs and lax reimbursement guidelines will limit market expansion.

The number of patients receiving treatment for inflammatory bowel disease is lower in underdeveloped nations due to a lack of knowledge about the condition. Furthermore, it is anticipated that in the upcoming years, patients' use of inflammatory bowel disease treatments will be restricted due to the high cost of therapy, which includes both medication and additional expenses.

The yearly mean expenditure per patient for UC and CD in the United States ranged from USD 6217 to USD 11,477 and USD 11,034 to USD 18,932, respectively, according to a 2023 study published in BMC Gastroenterology.

Furthermore, biologics are being used more frequently to treat Crohn's disease and ulcerative colitis; nevertheless, the high expense of biologics treatment is restricting market expansion. For instance, in the United Kingdom, Adalimumab costs around USD 12,343 per person annually, according to the National Center for Biotechnology Information (NCBI).

The lack of reimbursement for IBD therapy in developing nations like China, Russia, and India restricts the use of these medications in the area. Thus, the demand for inflammatory bowel disease treatments is being constrained by the high cost of inflammatory bowel disease drugs and the absence of reimbursement schemes in underdeveloped nations.


High treatment costs

The market for treatments for inflammatory bowel disease (IBD) is severely hampered by high treatment costs. Patients and healthcare systems may experience financial difficulty due to the high cost of biologic therapy, which are frequently the most effective treatments. Access to necessary therapies may be restricted by these expenses, particularly in areas with low or middling incomes. Widespread adoption is hampered by the high cost of pharmaceuticals and the need for continuous therapy. Furthermore, inadequate insurance coverage may lead to patients delaying or skipping necessary care, which could have an impact on the course of therapy.


Inflammatory Bowel Disease Treatment Market Overview by Regions

The market for treatments for inflammatory bowel disease (IBD) is growing worldwide, with North America leading the way thanks to its sophisticated healthcare system, high treatment uptake, and significant research expenditures. With increased knowledge and accessibility to biologic treatments, Europe is a close follower. Due to rising IBD prevalence and better access to healthcare, the Asia-Pacific region is expanding quickly. Despite their slower adoption rates, the Middle East and Africa are steadily growing as awareness and healthcare systems advance. Treatment availability, economic factors, and healthcare access all affect regional disparities.


Inflammatory Bowel Disease Treatment Market Overview by Regions

United States Inflammatory Bowel Disease Treatment Market

The market for treatments for inflammatory bowel disease (IBD) in the US is expanding significantly due to new medications and rising patient desire for easier access to care. The U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Company's Biologics License Application (BLA) in September 2023 for the investigational subcutaneous (SC) delivery of ENTYVIO (vedolizumab). In response to the increased demand for practical, efficient treatment choices, this application seeks to increase the use of ENTYVIO for maintenance therapy in individuals with moderately to highly active Crohn's disease.

Additionally, Coherus BioScience, Inc. introduced YUSIMRY (adalimumab-aqvh) in July 2023, which resulted in a significant price drop for the market. This adalimumab biosimilar addresses the high treatment costs associated with biologic therapy by providing a less expensive substitute for the name-brand medication Humira. By expanding access to innovative treatments and assisting in the management of the increasing incidence of IBD in the nation, these developments support the expanding IBD treatment market in the United States. The market is anticipated to grow even further with sustained innovation and price competitiveness, which will benefit patients and healthcare systems alike.


Germany Inflammatory Bowel Disease Treatment Market

The market for treatments for inflammatory bowel disease (IBD) in Germany is fueled by a strong healthcare system, rising awareness, and easy access to cutting-edge treatments. The use of biologic treatments has increased in the nation, particularly for moderate-to-severe forms of IBD, such as Crohn's disease and ulcerative colitis. Biosimilars, like substitutes for adalimumab, are becoming more and more well-liked as the need for individualized and affordable treatments increases. New IBD treatments are also developed because to Germany's robust research environment, which promotes market growth and better patient outcomes.


India Inflammatory Bowel Disease Treatment Market

The market for treatments for inflammatory bowel disease (IBD) is expanding significantly in India due to improvements in healthcare infrastructure and an increase in IBD prevalence. More people are seeking medical care as a result of growing knowledge of IBD, which raises the need for efficient treatments. Although biologic treatments are becoming more popular, they are still expensive and frequently out of reach for many people because of financial constraints. The market is expanding as a result of biosimilars becoming more reasonably priced substitutes. Further market expansion in India is also anticipated due to improvements in diagnostics and treatment options as well as a stronger emphasis on managing chronic diseases.


Saudi Arabia Inflammatory Bowel Disease Treatment Market

The market for treatments for inflammatory bowel disease (IBD) in Saudi Arabia is expanding as a result of higher awareness, better healthcare facilities, and an increase in the prevalence of IBD. Treatment options are growing as biologic treatments, especially more recent biologics and biosimilars, become more widely available. The government's emphasis on managing chronic diseases and its investments in healthcare also support market expansion. The market for IBD treatments in Saudi Arabia is anticipated to grow over the next several years due to improved diagnosis and increased patient demand.


Inflammatory Bowel Disease Treatment Market Segments

Drug Class – Market breakup in 7 viewpoints:
1. TNF Inhibitors
2. Anti-Integrin
3. IL inhibitors
4. JAK inhibitors
5. Corticosteroids
6. Aminosalicylates
7. Others


Disease Indication – Market breakup in 2 viewpoints:
1. Ulcerative Colitis
2. Crohn's Disease


Distribution Channel – Market breakup in 3 viewpoints:
1. Hospital Pharmacy
2. Retail Pharmacy
3. Online Pharmacy


Countries – Market breakup in 25 Countries:
North America

1. United States
2. Canada

Europe

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey

Asia Pacific

1. China
2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

1. South Africa
2. Saudi Arabia
3. UAE


All the Key players have been covered from 5 Viewpoints:
• Overview
• Key Persons
• Recent Development & Strategies
• Product Portfolio
• Financial Insights


Company Analysis:
1. Abbott Laboratories
2. AbbVie Inc.
3. Allergan Therapeutics LLC
4. Bausch Health Companies Inc. (Salix Pharmaceuticals)
5. Bristol-Myers Squibb Company
6. Johnson & Johnson
7. Novartis AG
8. Pfizer Inc.


Key Questions Answered in Report:
1. How big is the inflammatory bowel disease treatment industry?
The global inflammatory bowel disease treatment market size was valued at US$ 22.91 billion in 2024 and is expected to reach US$ 33.99 billion in 2033.

2. What is the inflammatory bowel disease treatment industry growth rate?
The global inflammatory bowel disease treatment market is expected to expand at a compound annual growth rate (CAGR) of 4.48% from 2025 to 2033.

3. Who are the key players in inflammatory bowel disease treatment industry?
The top inflammatory bowel disease treatment companies are Abbott Laboratories, AbbVie Inc., Allergan Therapeutics LLC, Bausch Health Companies Inc. (Salix Pharmaceuticals), Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG and Pfizer Inc.

4. What are the factors driving the inflammatory bowel disease treatment industry?
The growth of the Inflammatory Bowel Disease treatment market is driven by increasing disease prevalence, advancements in biologic therapies, rising awareness, improved diagnostics, and growing healthcare investments in specialized treatments.

5. Which Region held the largest market share in the inflammatory bowel disease treatment industry?
North America is expected to hold the largest market share in the industry.

6. What segments are covered in the inflammatory bowel disease treatment market report?
Drug Class, Disease Indication, Distribution Channel and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research & Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Inflammatory Bowel Disease Treatment Market


6. Market Share Analysis
6.1 Drug Class
6.2 Disease Indication
6.3 Distribution Channel
6.4 Country


7. Drug Class
7.1 TNF Inhibitors
7.2 Anti-Integrin
7.3 IL inhibitors
7.4 JAK inhibitors
7.5 Corticosteroids
7.6 Aminosalicylates
7.7 Others


8. Disease Indication
8.1 Ulcerative Colitis
8.2 Crohn's Disease


9. Distribution Channel
9.1 Hospital Pharmacy
9.2 Retail Pharmacy
9.3 Online Pharmacy


10. Country
10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium

10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Thailand
10.3.7 Malaysia
10.3.8 Indonesia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 UAE


11. Porter’s Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Company Analysis
13.1 Abbott Laboratories
13.1.1 Overview
13.1.2 Key Persons
13.1.3 Recent Development & Strategies
13.1.4 Product Portfolio
13.1.5 Financial Insights

13.2 AbbVie Inc.
13.2.1 Overview
13.2.2 Key Persons
13.2.3 Recent Development & Strategies
13.2.4 Product Portfolio
13.2.5 Financial Insights

13.3 Allergan Therapeutics LLC
13.3.1 Overview
13.3.2 Key Persons
13.3.3 Recent Development & Strategies
13.3.4 Product Portfolio
13.3.5 Financial Insights

13.4 Bausch Health Companies Inc. (Salix Pharmaceuticals)
13.4.1 Overview
13.4.2 Key Persons
13.4.3 Recent Development & Strategies
13.4.4 Product Portfolio
13.4.5 Financial Insights

13.5 Bristol-Myers Squibb Company
13.5.1 Overview
13.5.2 Key Persons
13.5.3 Recent Development & Strategies
13.5.4 Product Portfolio
13.5.5 Financial Insights

13.6 Johnson & Johnson
13.6.1 Overview
13.6.2 Key Persons
13.6.3 Recent Development & Strategies
13.6.4 Product Portfolio
13.6.5 Financial Insights

13.7 Novartis AG
13.7.1 Overview
13.7.2 Key Persons
13.7.3 Recent Development & Strategies
13.7.4 Product Portfolio
13.7.5 Financial Insights

13.8 Pfizer Inc.
13.8.1 Overview
13.8.2 Key Persons
13.8.3 Recent Development & Strategies
13.8.4 Product Portfolio
13.8.5 Financial Insights